Arrowhead Pharmaceuticals, Inc.
ARWRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. At a $10.47B market cap, Arrowhead Pharmaceuticals, Inc. ranks as a large-cap company within healthcare. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Market Cap
$10.47B
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
-16.28
EPS (TTM)
$-2.27
EPS (Fwd)
$-4.57
ROE
-42.4%
ROA
-7.2%
Cash
$1.78B
Total Debt
$1.38B
Free CF
-$46.1M
52W Change
343.3%
Annual Financials
Cash vs Debt
With $1.78B in cash and $1.38B in debt, ARWR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$46.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $243.2M to $829.4M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arrowhead Pharmaceuticals, Inc. and its sector.